ATE357459T1 - Antikörper gegen mensliches il-12 - Google Patents

Antikörper gegen mensliches il-12

Info

Publication number
ATE357459T1
ATE357459T1 AT99904780T AT99904780T ATE357459T1 AT E357459 T1 ATE357459 T1 AT E357459T1 AT 99904780 T AT99904780 T AT 99904780T AT 99904780 T AT99904780 T AT 99904780T AT E357459 T1 ATE357459 T1 AT E357459T1
Authority
AT
Austria
Prior art keywords
antibodies
human
Prior art date
Application number
AT99904780T
Other languages
English (en)
Inventor
Maurcie Kent Gately
David Howard Presky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22106938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE357459(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE357459T1 publication Critical patent/ATE357459T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
AT99904780T 1998-01-23 1999-01-15 Antikörper gegen mensliches il-12 ATE357459T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7233398P 1998-01-23 1998-01-23

Publications (1)

Publication Number Publication Date
ATE357459T1 true ATE357459T1 (de) 2007-04-15

Family

ID=22106938

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07005606T ATE553129T1 (de) 1998-01-23 1999-01-15 Antikörper gegen humanes il-12
AT99904780T ATE357459T1 (de) 1998-01-23 1999-01-15 Antikörper gegen mensliches il-12

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07005606T ATE553129T1 (de) 1998-01-23 1999-01-15 Antikörper gegen humanes il-12

Country Status (18)

Country Link
US (1) US6225117B1 (de)
EP (2) EP1049717B1 (de)
JP (3) JP4481489B2 (de)
KR (1) KR100764256B1 (de)
CN (2) CN100374466C (de)
AR (2) AR014459A1 (de)
AT (2) ATE553129T1 (de)
AU (1) AU759624B2 (de)
BR (1) BR9907743A (de)
CA (1) CA2318052C (de)
CY (2) CY1106594T1 (de)
DE (1) DE69935574T2 (de)
DK (2) DK1049717T3 (de)
ES (2) ES2284242T3 (de)
PT (2) PT1818343E (de)
TR (1) TR200002145T2 (de)
WO (1) WO1999037682A2 (de)
ZA (1) ZA99452B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399379B1 (en) 1992-09-29 2002-06-04 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p35 subunit expression
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7026456B1 (en) * 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US6448081B1 (en) 2001-05-07 2002-09-10 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p40 subunit expression
DE69927520T2 (de) * 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont Verwendung von il-12 antikörpern zur behandlung von psoriasis
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
CA2399387C (en) * 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
AU2003239226A1 (en) * 2002-06-11 2003-12-22 Isis Pharmaceuticals, Inc. METHODS FOR BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION WITH INTERLEUKIN 12 p35 INHIBITORS
ES2311122T3 (es) * 2002-12-30 2009-02-01 Biogen Idec Ma Inc. Antagonistas de kim-1 y uso para la modulacion del sistema inmune.
EP1711527A4 (de) * 2003-12-15 2008-09-03 Dendreon Corp Hla-dr-spezifische antikörper, zusammensetzungen und verfahren
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
KR20070094927A (ko) 2004-12-21 2007-09-27 센토코 인코포레이티드 항-ｉｌ-12 항체, 에피토프, 조성물, 방법 및 용도
DE602006016413D1 (de) 2005-03-02 2010-10-07 Biogen Idec Inc Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen
US7700739B2 (en) * 2005-06-30 2010-04-20 Abbott Laboratories IL-12/p40 binding proteins
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
NZ578065A (en) 2007-01-16 2012-09-28 Abbott Lab Methods for treating psoriasis with an antibody which binds to an epitope
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
NZ587765A (en) 2008-03-18 2013-02-22 Abbott Lab Methods for treating psoriasis
US8563697B2 (en) 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
KR20140048229A (ko) * 2009-09-14 2014-04-23 애브비 인코포레이티드 건선을 치료하는 방법
CN103275222B (zh) * 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
AU2017241776A1 (en) 2016-03-29 2018-10-11 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
DK3883606T5 (da) 2018-09-24 2024-01-02 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5536657A (en) 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7119248B1 (en) * 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US5809360A (en) * 1996-08-07 1998-09-15 Agfa Division - Bayer Corporation Cassette for storing and accessing plates within an automated plate handler
IL123888A0 (en) * 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies

Also Published As

Publication number Publication date
BR9907743A (pt) 2000-10-17
WO1999037682A2 (en) 1999-07-29
EP1818343A3 (de) 2007-08-22
AU759624B2 (en) 2003-04-17
US6225117B1 (en) 2001-05-01
AU2517799A (en) 1999-08-09
CY1106594T1 (el) 2012-01-25
CN100374466C (zh) 2008-03-12
WO1999037682A3 (en) 1999-11-18
JP2002501085A (ja) 2002-01-15
AR014459A1 (es) 2001-02-28
EP1049717B1 (de) 2007-03-21
ATE553129T1 (de) 2012-04-15
CN101274962A (zh) 2008-10-01
KR20010034315A (ko) 2001-04-25
KR100764256B1 (ko) 2007-10-05
DE69935574D1 (de) 2007-05-03
ZA99452B (en) 1999-07-23
PT1049717E (pt) 2007-05-31
EP1818343B1 (de) 2012-04-11
JP2009197008A (ja) 2009-09-03
EP1818343A2 (de) 2007-08-15
DE69935574T2 (de) 2007-12-06
CA2318052A1 (en) 1999-07-29
DK1049717T3 (da) 2007-07-30
PT1818343E (pt) 2012-07-12
EP1049717A2 (de) 2000-11-08
JP4481489B2 (ja) 2010-06-16
CY1112927T1 (el) 2016-04-13
ES2284242T3 (es) 2007-11-01
DK1818343T3 (da) 2012-07-16
AR061801A2 (es) 2008-09-24
ES2386262T3 (es) 2012-08-14
CA2318052C (en) 2012-07-03
CN1288468A (zh) 2001-03-21
JP2013139458A (ja) 2013-07-18
TR200002145T2 (tr) 2000-11-21

Similar Documents

Publication Publication Date Title
ATE553129T1 (de) Antikörper gegen humanes il-12
EE200000470A (et) Inimese CD40-vastased antikehad
ID22508A (id) Trokar untuk memasukkan implant-implant
NO20005488D0 (no) Hematopoetisk stimulering
NO20004758L (no) Vaksinesammensetning
DK1075512T3 (da) Cytotoxinbaseret biologisk indkapsling
ID27841A (id) Turunan-turunan biaril terapeutik
NO20006191D0 (no) Vaksine
LV12624B (lv) Tienilazolilalkosietanamini to iegusanas panemiens un pielietojums medikamentu legusana
NO993443L (no) Kabinstruktur
DE29822563U1 (de) Implantat
NO20005599L (no) Vaksine
ATE278712T1 (de) Antikörper gegen plazentaprotein 13
ID24759A (id) Metoda untuk meningkatkan volume tulang
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
DE29822843U1 (de) Krückstock
DE29801087U1 (de) Anatomisches Präparat
ES1042932Y (es) Inyector-reactor biologico
DE29812195U1 (de) Bambusschirm
KR980000095U (ko) 벌꿀 채밀기
DE29805467U1 (de) Propoliszubereitung
NO975301A (no) Innluftstenger
DE29816476U1 (de) Sonnenschirm
FI3598U1 (fi) Paistokeppi
DE29819216U1 (de) Schatulle

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1049717

Country of ref document: EP